Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NSCLC Harboring EGFR Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06563999
What this trial is testing

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Who this might be right for
Lung Cancer Stage IIIMutation
Sun Yat-sen University 120
Testing effectiveness (Phase 2)Looking for participantsNCT06706076
What this trial is testing

BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics 675
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Early research (Phase 1)Active Not RecruitingNCT03993873
What this trial is testing

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Turning Point Therapeutics, Inc. 95
Testing effectiveness (Phase 2)Study completedNCT05258279
What this trial is testing

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Who this might be right for
Non-squamous Non-small-cell Lung CancerEGFR Activating Mutation
Juntendo University 30
Testing effectiveness (Phase 2)Looking for participantsNCT06043817
What this trial is testing

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Who this might be right for
Non-Small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament 345
Testing effectiveness (Phase 2)UnknownNCT01955421
What this trial is testing

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Who this might be right for
Advanced Stage Non Small Cell Lung Cancer
Sun Yat-sen University 224
Testing effectiveness (Phase 2)Ended earlyNCT01953926
What this trial is testing

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Who this might be right for
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc. 582
Early research (Phase 1)Study completedNCT04858958
What this trial is testing

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc. 90
Testing effectiveness (Phase 2)Ended earlyNCT02949843
What this trial is testing

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Who this might be right for
EGFR Activating MutationRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
Wake Forest University Health Sciences 19
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06672068
What this trial is testing

TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

Who this might be right for
NSCLC
TYK Medicines, Inc 60
Testing effectiveness (Phase 2)Looking for participantsNCT05271916
What this trial is testing

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital 140
Early research (Phase 1)Ended earlyNCT05578092
What this trial is testing

MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Who this might be right for
Solid TumorAdvanced Solid TumorNon Small Cell Lung Cancer+1 more
Mirati Therapeutics Inc. 64
Large-scale testing (Phase 3)UnknownNCT01951469
What this trial is testing

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerBrain MetastasesEGFR Mutation
Sun Yat-sen University 160
Not applicableStudy completedNCT02450591
What this trial is testing

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Who this might be right for
Oligometastatic Lung Adenocarcinoma
Memorial Sloan Kettering Cancer Center 4
Not applicableAvailableNCT06761976
What this trial is testing

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Who this might be right for
Advanced Non-small Cell Lung CancerCancer
Bayer
Testing effectiveness (Phase 2)Looking for participantsNCT05967689
What this trial is testing

Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Who this might be right for
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc. 220
Not applicableApproved For MarketingNCT01649284
What this trial is testing

Afatinib Expanded Access Program

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim
Large-scale testing (Phase 3)WithdrawnNCT03529084
What this trial is testing

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Who this might be right for
Carcinoma, Non-small Cell Lung
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Looking for participantsNCT05099172
What this trial is testing

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation
Bayer 400
Next Page